---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-015582"
form_type: "8-K"
ticker: "CLSDQ"
cik: "0001539029"
company_name: "Clearside Biomedical, Inc."
filed_at: "2022-08-08T23:59:59+00:00"
generated_at: "2026-06-24T02:46:49.383712+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Clearside Biomedical enters royalty financing with HealthCare Royalty for up to $65M

## Summary
- Upfront cash of $32.5M; additional $12.5M escrow tied to XIPERE sales milestone, plus up to $20M second milestone.
- HealthCare Royalty receives royalties from XIPERE and SCS Microinjector license deals until 2.5x (or 3.4x) payback achieved.
- Proceeds intended to support CLS-AX (axitinib injectable suspension) clinical program via suprachoroidal injection.
- Deal excludes Clearside's internal pipeline and future in-licensed assets; non-dilutive capital.
- Transaction expected to close in August 2022; JMP Securities acted as financial advisor.

## SEC filing metadata
- accession: 0000950170-22-015582
- form_type: 8-K
- ticker: CLSDQ
- cik: 0001539029
- company_name: Clearside Biomedical, Inc.
- filed_at: 2022-08-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1539029/000095017022015582/0000950170-22-015582-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1539029/000095017022015582/clsd-20220808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-015582
- JSON: https://secwatch.observer/filing/0000950170-22-015582.json
- Plain text: https://secwatch.observer/filing/0000950170-22-015582.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.